000106592 001__ 106592
000106592 005__ 20220425105233.0
000106592 0247_ $$2doi$$a10.1111/ene.14431
000106592 0248_ $$2sideral$$a119612
000106592 037__ $$aART-2020-119612
000106592 041__ $$aeng
000106592 100__ $$aIrimia, P.
000106592 245__ $$aEstimating the savings associated with a migraine-free life: results from the Spanish Atlas
000106592 260__ $$c2020
000106592 5060_ $$aAccess copy available to the general public$$fUnrestricted
000106592 5203_ $$aBackground and purpose: Migraine is a common and costly neurological disorder. The aims of this study were to quantify the costs of chronic (CM) and episodic migraine (EM) in Spain, evaluating the impact of psychiatric comorbidities and disability, and to estimate the economic savings associated with reducing the number of migraine-days by 50%.
Methods: This was an observational, cross-sectional analysis of data from migraine patients who participated in the Spanish Migraine Atlas. The participants were invited to complete a structured questionnaire including the following scales: the Headache Needs Assessment, the Hospital Anxiety and Depression Scale, and the Migraine Disability Assessment Scale (MIDAS).
Results: A total of 475 patients were included, of whom 187 had CM (39.4%). Total costs per patient/year were: €16 578.2 ± €34 568.1 for CM and €6227.8 ± €6515.7 for EM. A higher degree of disability, according to MIDAS, significantly increased the total cost of migraine, while the presence of psychiatric comorbidity increased costs for EM patients only. A reduction of 1 migraine-day per month decreased average total costs by €744.14 per patient/year for EM and €663.20 per patient/year for CM, while a reduction in the number of migraine-days by 50% would result in economic savings of €2232.44 per patient/year (R2 = 0.927) for EM and €6631.99 per patient/year (R2 = 0.886) for CM.
Conclusions: The costs associated with migraine were driven by migraine frequency and the degree of disability, whereas psychiatric comorbidity only influenced the cost of EM. These results highlight the need to optimize migraine management to reduce the economic migraine burden. Future studies are needed to confirm our results.
000106592 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000106592 590__ $$a6.089$$b2020
000106592 591__ $$aNEUROSCIENCES$$b53 / 273 = 0.194$$c2020$$dQ1$$eT1
000106592 591__ $$aCLINICAL NEUROLOGY$$b30 / 208 = 0.144$$c2020$$dQ1$$eT1
000106592 592__ $$a1.881$$b2020
000106592 593__ $$aNeurology (clinical)$$c2020$$dQ1
000106592 593__ $$aNeurology$$c2020$$dQ1
000106592 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000106592 700__ $$aGarrido-Cumbrera, M.
000106592 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa, S.$$uUniversidad de Zaragoza
000106592 700__ $$aBraçe, O.
000106592 700__ $$aColomina, I.
000106592 700__ $$aBlanch, C.
000106592 700__ $$aPozo-Rosich, P.
000106592 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000106592 773__ $$g27, 12 (2020), 2616-2624$$pEur. j. neurol.$$tEUROPEAN JOURNAL OF NEUROLOGY$$x1351-5101
000106592 8564_ $$s1464218$$uhttps://zaguan.unizar.es/record/106592/files/texto_completo.pdf$$yPostprint
000106592 8564_ $$s1336014$$uhttps://zaguan.unizar.es/record/106592/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000106592 909CO $$ooai:zaguan.unizar.es:106592$$particulos$$pdriver
000106592 951__ $$a2022-04-25-10:37:19
000106592 980__ $$aARTICLE